Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02454270 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies
A Phase 1 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT02454270 is a Phase 1 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 59 participants.
The verdict
NCT02454270, a Phase 1 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, dose-limiting toxicities (any harmful effect of a drug) (DLT), maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and preliminary clinical activity of duvortuxizumab when administered intravenously to participants with relapsed or refractory B-cell malignancies \[diffuse-large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL)\].
Interventions
- DRUG Part 1 (Dose Escalation): Duvortuxizumab
- DRUG Part 2 (Dose Expansion): Duvortuxizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2015-06-15 |
| Est. Completion | 2018-07-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02454270
The ClinicalTrials.gov registry entry for NCT02454270 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Part 1 (Dose Escalation): Duvortuxizumab is the first listed.
NCT02454270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02454270 about?
NCT02454270 is a clinical study titled "A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies". The purpose of this study is to evaluate the safety, tolerability, dose-limiting toxicities (any harmful effect of a drug) (DLT), maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and preliminary clinical activity of duvortuxizumab when administered intravenously to participants with rel...
What is the current status of trial NCT02454270?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2015-06-15. Estimated completion is 2018-07-26.
What interventions are being tested in trial NCT02454270?
The interventions under investigation include: Part 1 (Dose Escalation): Duvortuxizumab (DRUG), Part 2 (Dose Expansion): Duvortuxizumab (DRUG).
Who is sponsoring clinical trial NCT02454270?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.